| PDF (7MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-339394
- DOI to cite this document:
- 10.5283/epub.33939
Abstract
The capacity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to selectively induce cell death in malignant cells triggered numerous attempts for therapeutic exploitation. In clinical trials, however, TRAIL did not live up to the expectations, as tumors exhibit high rates of TRAIL resistance in vivo. Response to anti-cancer therapy is determined not only by cancer cell intrinsic ...

Owner only: item control page